內(nèi)皮抑素(ES)真核蛋白
Eukaryotic Endostatin (ES)
- 編號EPA542Hu61
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 來源真核表達
- 宿主293F cell
- 內(nèi)毒素水平<1.0EU per 1ug (determined by the LAL method)
- 亞細胞定位分泌
- 預(yù)測分子量21.6kDa
- 實際分子量21kDa(差異分析請參閱說明書)
- 片段與標簽His1154~Ser1335 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液，（pH8.0,含有1mM EDTA, 1mM DTT, 5% Trehalose and Proclin300）
- 性狀凍干粉
- 純度> 97%
- 等電點9.1
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1320¥ 3300¥ 6600¥ 19800¥ 49500
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Gene sequencing
SDS-PAGE圖
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
PBS或其它。
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA542Hu61 | 內(nèi)皮抑素(ES)活性蛋白 | Cell?culture;?Activity?Assays. |
| EPA542Hu61 | 內(nèi)皮抑素(ES)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| CPA542Hu31 | 內(nèi)皮抑素(ES)鑰孔血藍蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| PAA542Hu01 | 內(nèi)皮抑素(ES)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA542Hu06 | 內(nèi)皮抑素(ES)多克隆抗體 | WB; IHC; ICC; IP. |
| WEA542Hu | 內(nèi)皮抑素(ES)檢測試劑盒(酶聯(lián)免疫吸附試驗法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SEA542Hu | 內(nèi)皮抑素(ES)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| CEA542Hu | 內(nèi)皮抑素(ES)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA542Hu | 內(nèi)皮抑素(ES)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA542Hu11 | 內(nèi)皮抑素(ES)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Cancer Immunology | Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice[SpringerLink: u38777121t6660l5] |
| Journal of Fluoresence | Erythrocyte Protoporphyrin Fluorescence as a Biomarker for Monitoring Antiangiogenic Cancer Therapy[SpringerLink: 4v306130302257w0] |
| The Journal of Gene Medicine | Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma[Wiley: source] |
| Biomedicine & Pharmacotherapy | Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma[ScienceDirect: S075333221100151X] |
| Science Alert | Antiangiogenic Activities of Cinnamon, Black and Green Tea Extracts on Experimentally Induced Breast Cancer in Rats[Scialert: Source] |
| The Journal of Immunology | Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer[PubMed: PMC3619527] |
| Prostaglandins & Other Lipid Mediators | Promotion of adipogenesis by an EP2 receptor agonist via stimulation of angiogenesis in pulmonary emphysema[Pubmed:24911647] |
| American Journal of Physiology - Heart and Circulatory Physiology | Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?[Source] |
| shock | Angiogenesis inhibitor endostatin protects mice with sepsis from multiple organ dysfunction syndrome[PubMed: 26125086] |
| Clin Rev Allergy Immunol | Endothelial Dysfunction and Nailfold Videocapillaroscopy Pattern as Predictors of Digital Ulcers in Systemic Sclerosis: a Cohort Study and Review of the Literature[PubMed: 26142066] |
| Angiologia e Cirurgia Vascular | Peripheral vasculopathy in Raynaud phenomenon: Vascular disease biomarkers[science:S1646706X16300052] |
| Clinical Rheumatology | Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis[Pubmed:26920752] |
| Blood biomarker for early blood brain barrier disruption in ischemic stroke[patent:US20170199205A1] |